Effects of dopamine antagonists in a two-way active avoidance procedure in rats: Interactions with 8-OH-DPAT, ritanserin, and prazosin

Psychopharmacology

Volumn 128, Issue 2, 1996, Pages 191-197

  Prinssen, E P M ^a   Kleven, Mark S ^a   Koek, Wouter ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

1 adrenoceptor; conditioned avoidance response; dopamine D2 receptor; neuroleptics; rats; schizophrenia; serotonin 5 HT2 receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PRAZOSIN; RACLOPRIDE; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG POTENTIATION; ESCAPE BEHAVIOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AVOIDANCE LEARNING; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; PRAZOSIN; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RITANSERIN; SALICYLAMIDES; SEROTONIN AGENTS;

EID: 0029822710     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050124     Document Type: Article

References (52)

1. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5
2. 3H]SCH 23390 binding in vivo. Eur J Pharmacol 12:143-144
3. Archer T, Ögren SO, Johansson G, Ross SB (1982) DSP4-induced two-way active avoidance impairment in rats: involvement of central and not peripheral noradrenaline depletion. Psychopharmacology 76:303-309
4. Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329
5. Arnt J, Hyttel J, Bach-Lauritsen T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319-324
6. Baldessarini RJ, Tarsy D (1980) Dopamine and the pathophysiology of dyskinesias induced by anti-psychotic drugs. Ann Rev Neurosci 3:23-41
7. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160 [Suppl 17] 12-16
8. Brody D, Adler LA, Kim T, Angrist B, Rotrosen J (1990) Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 10:68-69
9. Broekkamp CLE, Oosterloo SK, Berendsen HHG, Van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338:191-195
10. Burki HR (1986) Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn-Schmiedeberg's Arch Pharmacol 332:258-266
11. Chiodo L, Bunney R (1985) Possible mechanisms by which repeated dozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544
12. Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action. Eur J Pharmacol 136:371-375
13. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
14. Creese I, Burt DR, Synder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
15. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 163:451-455
16. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1-78
17. Ellenbroek BA, Peeters BW, Honig WM, Cools AR (1987) The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 93:343-348
18. 2-receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103-108
19. Ellenbroek BA, Prinssen EPM, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1-8
20. Evenden JL (1992) Effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) after repeated administration on a conditioned avoidance response (CAR) in the rat. Psychopharmacology 109:134-144
21. Goff DC, Midha KK, Brotman AW, McCormick S, Waits M, Amico ET (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11:193-197
22. 1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuro-Psychopharmacol Biol Psychiatry 18:803-821
23. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
24. Janssen PAJ, Niemegeers CJE, Schellekens KHL (1966) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Part III: The subcutaneous and oral activity in rats and dogs of 56 neuroleptic drugs in the jumping box test. Arzneimittelforschung 16:339-346
25. 3 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 124:35-39
26. 1C receptors. Neurosci Biobehav Rev 16:95-105
27. 3H-raclopride. Biochem Pharmacol 34: 2251-2259
28. Kuribara H, Tadakoro S (1981) Correlation between anti-avoidance activities of anti-psychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 14:181-192
29. Le Fur G, Burgevin M, Malgouris C, Uzan A (1979) Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic postsynaptic receptors. Neuropharmacology 18:591-594
30. 2 receptors. Psychopharmacology 112[Suppl.]:S40-S54
31. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97:456-461
32. Marsden C, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55-72
33. Matthysse S (1974) Dopamine and the pharmacology of schizophrenia: the state of the evidence. J Psychiatry Res 11:107-113
34. McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC (1983) Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. J Neurosci 3:733-738
35. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
36. 2 pKi values. J Pharmacol Exp Ther 251:238-246
37. Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217
38. Ögren S-O, Archer T (1994) Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology 114:383-391
39. Pantelis C, Barnes TRE (1993) Acute exacerbation of psychosis with buspirone? J Psychopharmacol 7:295-300
40. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726
41. Prinssen EPM, Ellenbroek BA, Cools AR (1994a) Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test. Br J Pharmacol 112:769-774
42. Prinssen EPM, Ellenbroek BA, Cools AR (1994b) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170
43. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17:247-261
44. Sathananthan GL, Sanghvi I, Phillips N, Gershon S (1975) MJ 9022: correlation between neuroleptic potential and stereotypy. Curr Ther Res 18:701-705
45. Schotte A, De Bruyckere K, Janssen PFM, Leysen JE (1989) Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res 500:295-301
46. Schotte A, Bonaventure P, Janssen PFM, Leysen JE (1995) In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69:399-412
47. Seeman P, Lee T, Choa-Wong M, Wong K (1976) Anti-psychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
48. 1A agonists and partial agonists suppress conditioned avoidance responding in rats. Soc Neurosci Abstr 18:549
49. 1B-adrenoceptors. Eur J Pharmacol 238:407-410
50. Strange PG (1991) Neuroleptic drugs and dopamine receptors. Am J Psychiatry 148:1101
51. Wadenberg M-L, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53
52. Wiesel F-A, Nordström A-L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114:31-38